Testing a gene therapy called TGX-007 for high grade glioma
Original title: Study of an AAV Mediated Dual-Payload Gene Therapy in Patients With High Grade Glioma
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early test in people to find a safe dose.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study tests a new gene therapy given as a shot into a brain tumor.
Who this trial is for. This study is for people with new or returning glioblastoma: A glioma that is given grade 4. Grade 4 is the highest grade there is. The tumor grows fast. Treatment usually starts soon after it is found. It often means surgery, and then radiation and chemotherapy. See the glossary who can have surgery. It tests TGX-007, a gene therapy given by a harmless virus, along with a pill called valacyclovir.
Where it stands. This trial has not reported results. The first part looks for a safe dose and the best dose to use. The second part will look at how well TGX-007 treats the tumor. Those answers are not in yet.
What this means, and what it doesn't
What it could mean: This is one of the ways new brain tumor drugs get tested. About 68 people ages 18 to 70 will take part. People get the shot into the tumor, then take valacyclovir by mouth for up to 21 days before surgery. If this sounds like your situation, you could ask your care team about it.
What it doesn't mean: This does not mean TGX-007 works. A trial is a test, not a proven treatment. Joining one is not a promise that you will get better. It is not a cure, and no one can say yet if it helps.
Source: ClinicalTrials.gov, October 23, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.